The serum level of OX40 was significantly higher in the MS patients compared to healthy subjects (9.08 ± 2.48 vs. 1.49 ± 0.54 ng/ml; P = 0.041). This evidence concerns the gene TNFRSF4 and myeloid sarcoma.